BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2325607)

  • 1. [Basic and clinical evaluation of measurement of pancreatic cancer associated antigen, SPan-1].
    Chung YS; Nakata B; Tanaka H; Kubo T; Satake K; Sowa M; Umeyama K
    Nihon Geka Gakkai Zasshi; 1990 Feb; 91(2):228-33. PubMed ID: 2325607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
    Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum concentration and immunohistochemical localization of SPan-1 antigen in pancreatic cancer. A comparison with CA19-9 antigen.
    Takeda S; Nakao A; Ichihara T; Suzuki Y; Nonami T; Harada A; Koshikawa T; Takagi H
    Hepatogastroenterology; 1991 Apr; 38(2):143-8. PubMed ID: 1855772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pancreatic oncofetal antigen (POA)].
    Mugitani H; Furue H; Kako M; Hirota F; Fuse K; Takahashi T; Sakamoto K; Yamada K; Suminaga M; Ezaki M; Judo R
    Gan To Kagaku Ryoho; 1983 Aug; 10(8):1737-43. PubMed ID: 6882002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
    Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
    Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum markers and clinical data in diagnosing pancreatic cancer: a contrastive approach.
    Fabris C; Del Favero G; Basso D; Piccoli A; Meggiato T; Angonese C; Plebani M; Leandro G; Burlina A; Naccarato R
    Am J Gastroenterol; 1988 May; 83(5):549-53. PubMed ID: 3163228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer].
    Safi F; Büchler M; Schenkluhn B; Beger HG
    Dtsch Med Wochenschr; 1984 Dec; 109(49):1869-73. PubMed ID: 6209082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue polypeptide antigen, galactosyltransferase isoenzyme II and pancreatic oncofetal antigen serum determination: role in pancreatic cancer diagnosis.
    Basso D; Fabris C; Panucci A; Del Favero G; Angonese C; Plebani M; Petrin P; Burlina A; Naccarato R
    Int J Pancreatol; 1988; 3 Suppl 1():S95-100. PubMed ID: 3145303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical significance of Span-1 antigen assay as a tumor marker].
    Satake K; Chung YS; Umeyama K
    Nihon Rinsho; 1990 Feb; 48 Suppl():1053-6. PubMed ID: 2355504
    [No Abstract]   [Full Text] [Related]  

  • 10. CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases.
    Piantino P; Andriulli A; Gindro T; Pecchio F; Masoero G; Cavallini G; Naccarato R; Dobrilla G
    Am J Gastroenterol; 1986 Jun; 81(6):436-9. PubMed ID: 3458359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis.
    Gentiloni N; Caradonna P; Costamagna G; D'Ostilio N; Perri V; Mutignani M; Febbraro S; Tinari N; Iacobelli S; Natoli C
    Am J Gastroenterol; 1995 Jul; 90(7):1069-72. PubMed ID: 7611198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
    Satake K; Kanazawa G; Kho I; Chung Y; Umeyama K
    Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl Tn antigen: (1). Evaluation of assay conditions and normal values. STN Study Group].
    Imura H; Mori T; Ohkura H; Ishii M; Ariyoshi H; Endo J; Kitao M; Takeda I; Kobayashi H; Inoue M
    Gan To Kagaku Ryoho; 1989 Sep; 16(9):3213-9. PubMed ID: 2782915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of pancreatic oncofetal antigen (POA) in the diagnosis of pancreatic cancer].
    Nishida K
    Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):601-8. PubMed ID: 6349542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CA 19-9 in serum and pancreatic juice: its role in the differential diagnosis of resectable pancreatic cancer from chronic pancreatitis.
    Malesci A; Evangelista A; Mariani A; Bersani M; Bonato C; Basilico M; Montorsi M; Beretta E
    Int J Pancreatol; 1988; 3 Suppl 1():S119-23. PubMed ID: 3209865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].
    Yang YC; Zhao YP; Liao Q; Zhang TP; Hu Y; Dai MH
    Zhonghua Wai Ke Za Zhi; 2009 Jul; 47(13):999-1001. PubMed ID: 19957811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of CA 15-3 radioimmunoassay].
    Takemori Y; Odani H; Watanabe H; Ohta H; Satomura Y; Okai T; Sawabu N; Mai M; Hattori N; Hashimoto T
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):114-8. PubMed ID: 3467654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The diagnostic significance of carbohydrate antigen 19-9 in pancreatic carcinomas].
    Chen YF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Jun; 11(3):229-31. PubMed ID: 2529993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
    Blind PJ; Dahlgren ST
    Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
    Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
    Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.